Portal de Periódicos da CAPES

Antidepressants in Bipolar I Disorder: Never as Monotherapy

2014; American Psychiatric Association; Volume: 171; Issue: 10 Linguagem: Inglês

10.1176/appi.ajp.2014.14070826

1535-7228

Eduard Vieta,

Bipolar Disorder and Treatment

Back to table of contents Previous article Next article PerspectivesFull AccessAntidepressants in Bipolar I Disorder: Never as MonotherapyEduard Vieta, M.D.Eduard Vieta, M.D.Published Online:1 Oct 2014https://doi.org/10.1176/appi.ajp.2014.14070826AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail Bipolar depression is difficult to treat and prevent. Were this not so, the controversy about the use of antidepressants in patients with bipolar disorder would have faded away long ago. Physicians want the best for their patients, but they are often faced with difficult decisions related the benefit-risk profile of a treatment. And increasingly, patients have their own views on what they expect from treatment and which risks are worth taking and which not. At the end of the day, prescribing a treatment is an individualized decision based on knowledge, experience, empathy, and common sense. In an era of sophisticated genetic studies and dazzling neuroimaging tools, what makes a good psychiatrist is still sound clinical judgment. Last year, the Journal published an international consensus document on the use of antidepressants in bipolar disorder (1) that summarized the current evidence on their controversial efficacy and safety in bipolar disorder and provided a number of recommendations based on the state of the art. Recommendation 4 was "Antidepressant monotherapy should be avoided in bipolar I disorder" (1).The article by Viktorin et al. in this issue (2) confirms that antidepressant monotherapy can induce mania in the absence of a concurrent mood stabilizer. The authors used Swedish national registries to identify 3,240 people with bipolar disorder who started treatment with antidepressants, and they used a powerful within-individual design to control for confounding by disorder severity and genetic and early environmental factors. The study results clearly indicate that the risk of antidepressant-induced mania can be reduced by the prescription of an adjunctive mood stabilizer (lithium, valproate, or lamotrigine). The study does not, however, resolve the question of the efficacy of antidepressants in bipolar depression, which is, at best, arguable (1, 3, 4). While clinicians, and perhaps patients as well, tend to believe that antidepressants are effective in the treatment of bipolar depression—and even beyond, judging from the high rate of prescriptions in this and other studies (2, 5–7)—the evidence base is very weak, with the strongest findings coming from one trial that found the combination of fluoxetine and olanzapine to be superior to olanzapine alone (8). The other question that is not resolved in the Viktorin et al. study is the risk of switch in bipolar II disorder, given that data on hypomania were not captured. Thus, we are still left with the precise recommendation of not using antidepressant monotherapy in bipolar I disorder only (1).Questions and AnswersWhy were up to 35% of the patients with bipolar disorder in the Swedish registry treated with antidepressant monotherapy? Why are 15% of manic patients maintained on antidepressants despite the emergence of manic symptoms (6)? Why are serotonin-norepinephrine reuptake inhibitors so widely used (7) despite their reportedly having a greater risk of inducing mania than selective serotonin reuptake inhibitors (9, 10)? Why are so many patients with mixed states treated with antidepressants (11)? There may be several answers to these questions. First, it may simply be that antidepressants actually work. In fact, the evidence that they work is as weak as the evidence that they do not. The absence of financial incentives to seek a bipolar disorder indication (given that marketed antidepressants all have an indication in major depression, and the diagnostic cross-sectional criteria are the same for unipolar and bipolar depression), as opposed to the case for antipsychotics or anticonvulsants, has hindered research on these particular compounds for bipolar disorder. Second, the extensive use of antidepressants may be the result of limited treatment options, safety concerns about overuse of antipsychotics, extrapolation of antidepressant efficacy in other indications, and perhaps pressure from patients themselves asking for rapid relief of the unbearable pain of depression.Facts and RecommendationsThe Viktorin et al. Swedish registry study quite strikingly confirms early findings that antidepressant monotherapy is potentially harmful in bipolar disorder (12). Patients should be advised that without the addition of a mood stabilizer, there is a serious risk of manic switch. The study does not resolve the question of whether antidepressants should be used at all. Research progress has yielded several alternatives to antidepressants, with better evidence of efficacy, albeit far from ideal tolerability (13). In the current situation, it is truer than ever that every patient is a unique case deserving an individualized approach. Every patient should have the right to receive a detailed summary of reasonable treatment choices, psychoeducation on the illness, and objective information on the benefits and risks of each strategy. For many patients, antidepressants will not be the first-line recommendation, but perhaps those with a depressive-predominant polarity, with bipolar II disorder, or with a previous response to antidepressants may be candidates for an adjunctive antidepressant (1, 14–16). For patients with a history of mixed states and switching, with rapid cycling, or with a mania-predominant polarity, we may want to avoid prescribing antidepressants at all costs (1). We may want to look at comorbidities, especially those that may respond to antidepressant therapy, before we decide what to prescribe. Entering the era of personalized medicine, which in psychiatry at this point means stratifying patients according to clinical profile (17, 18), we want better evidence for what to do in patient subgroups, rather than simple registration trials that speak about the drug but not about the patients. As mentioned earlier, if excellent treatments were available for bipolar disorder, this editorial would not make sense, and therefore any effort to develop and market novel drugs must be applauded. Quetiapine, lurasidone, the combination of olanzapine and fluoxetine (an antidepressant!), and ECT are evidence-based treatment options (13), but it is obvious that many patients need something else. That "something else," at present, is what their physician or treatment team may figure out, after a careful investigation of the individual patient's needs and profile, from a number of available options, including adjunctive antidepressants. And the recipe is still the same: scientific knowledge, experience, empathy, and above all, common sense.From the Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS (Institute of Biomedical Research August Pi i Sunyer), CIBERSAM (Center for Biomedical Research Network on Mental Health), Barcelona, Spain.Address correspondence to Dr. Vieta (evieta@clinic.ub.es).Dr. Vieta has received research grants from Ferrer and Lundbeck and advisory board honoraria from Ferrer, Janssen, Lundbeck, Sunovion, and Takeda, and he has participated in CME educational activities for AstraZeneca, Ferrer, Lundbeck, Otsuka, Pfizer, Roche, and Sunovion. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.References1 Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E: The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170:1249–1262Link, Google Scholar2 Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PKE, Landén M: The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171:1067–1073Link, Google Scholar3 Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME: Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711–1722Crossref, Medline, Google Scholar4 McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH; EMBOLDEN II (Trial D1447C00134) Investigators: A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163–174Crossref, Medline, Google Scholar5 Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J: Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58:85–91Link, Google Scholar6 Rosa AR, Cruz N, Franco C, Haro JM, Bertsch J, Reed C, Aarre TF, Sanchez-Moreno J, Vieta E: Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry 2010; 71:1000–1006Crossref, Medline, Google Scholar7 Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, Moreno-Manzanaro M, Gonzalez MA, Bellivier F: Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol 2013; 16:1719–1732Crossref, Medline, Google Scholar8 Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079–1088Crossref, Medline, Google Scholar9 Vieta E, Martinez-Arán A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63:508–512Crossref, Medline, Google Scholar10 Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163:232–239Link, Google Scholar11 Valentí M, Pacchiarotti I, Rosa AR, Bonnín CM, Popovic D, Nivoli AM, Murru A, Grande I, Colom F, Vieta E: Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord 2011; 13:145–154Crossref, Medline, Google Scholar12 Pacchiarotti I, Valentí M, Colom F, Rosa AR, Nivoli AM, Murru A, Sánchez-Moreno J, Vieta E: Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord 2011; 129:321–326Crossref, Medline, Google Scholar13 Vieta E, Valentí M: Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013; 27:515–529Crossref, Medline, Google Scholar14 Grande I, de Arce R, Jiménez-Arriero MÁ, Lorenzo FG, Valverde JI, Balanzá-Martínez V, Zaragoza S, Cobaleda S, Vieta E; SIN-DEPRES Group: Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol 2013; 16:513–523Crossref, Medline, Google Scholar15 Nivoli AM, Colom F, Pacchiarotti I, Murru A, Scott J, Valentí M, Mazzarini L, Del Mar Bonnin C, Sánchez-Moreno J, Serretti A, Vieta E: Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options. Eur Neuropsychopharmacol 2013; 23:263–275Crossref, Medline, Google Scholar16 Pacchiarotti I, Valentí M, Bonnin CM, Rosa AR, Murru A, Kotzalidis GD, Nivoli AM, Sánchez-Moreno J, Vieta E, Colom F: Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol 2011; 21:362–369Crossref, Medline, Google Scholar17 Vieta E: The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr Scand 2014; 129:323–327Crossref, Medline, Google Scholar18 Schumann G, Binder EB, Holte A, de Kloet ER, Oedegaard KJ, Robbins TW, Walker-Tilley TR, Bitter I, Brown VJ, Buitelaar J, Ciccocioppo R, Cools R, Escera C, Fleischhacker W, Flor H, Frith CD, Heinz A, Johnsen E, Kirschbaum C, Klingberg T, Lesch KP, Lewis S, Maier W, Mann K, Martinot JL, Meyer-Lindenberg A, Müller CP, Müller WE, Nutt DJ, Persico A, Perugi G, Pessiglione M, Preuss UW, Roiser JP, Rossini PM, Rybakowski JK, Sandi C, Stephan KE, Undurraga J, Vieta E, van der Wee N, Wykes T, Haro JM, Wittchen HU: Stratified medicine for mental disorders. Eur Neuropsychopharmacol 2014; 24:5–50Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byTaiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 updateAsian Journal of Psychiatry, Vol. 82Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort studyJournal of Affective Disorders, Vol. 9An update on potential pharmacotherapies for cognitive impairment in bipolar disorder24 March 2023 | Expert Opinion on Pharmacotherapy, Vol. 11Uso de cariprazina en el trastorno bipolar: una revisión sistemática y aspectos prácticosPsiquiatría Biológica, Vol. 29, No. 3The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysisEuropean Neuropsychopharmacology, Vol. 60Neglected but not negligible aspects of antidepressants and their availability in bipolar depression29 July 2021 | Brain and Behavior, Vol. 11, No. 8Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention21 May 2021 | CNS Drugs, Vol. 35, No. 6Blood cytokines differentiate bipolar disorder and major depressive disorder during a major depressive episode: initial discovery and independent sample replicationBrain, Behavior, & Immunity - Health, Vol. 10Clinical correlates of seasonality in bipolar disorder: A specifier that needs specification?25 December 2020 | Acta Psychiatrica Scandinavica, Vol. 143, No. 2Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort studyJournal of Affective Disorders, Vol. 277The biology of aggressive behavior in bipolar disorder: A systematic reviewNeuroscience & Biobehavioral Reviews, Vol. 119"Do depressive and manic symptoms differentially impact on functioning in acute depression? Results from a large, cross-sectional study"Journal of Affective Disorders, Vol. 261Bipolar depression: the clinical characteristics and unmet needs of a complex disorder5 August 2019 | Current Medical Research and Opinion, Vol. 35, No. 11Identifying cognitive subgroups in bipolar disorder: A cluster analysisJournal of Affective Disorders, Vol. 246The Canadian Journal of Psychiatry, Vol. 64, No. 8Bipolar Disorder in Primary Care: Considerations in Management12 December 2018 | Current Treatment Options in Psychiatry, Vol. 5, No. 4, Vol. 250Clinical Psychopharmacology and Neuroscience, Vol. 16, No. 4Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features25 July 2017 | Acta Psychiatrica Scandinavica, Vol. 136, No. 4Journal of Affective Disorders, Vol. 219The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm5 November 2016 | International Journal of Neuropsychopharmacology, Vol. 55Bipolar disorderThe Lancet, Vol. 387, No. 10027The Lancet Psychiatry, Vol. 3, No. 12International Journal of NeuropsychopharmacologyA review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based NomenclatureEuropean Neuropsychopharmacology, Vol. 25, No. 12The role of comorbidities in duration of untreated illness for bipolar spectrum disordersJournal of Affective Disorders, Vol. 188Hyperprolactinemia and medications for bipolar disorder: Systematic review of a neglected issue in clinical practiceEuropean Neuropsychopharmacology, Vol. 25, No. 8Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studiesJournal of Affective Disorders, Vol. 172 Volume 171Issue 10 October 2014Pages 1023-1026 Metrics PDF download History Accepted 1 July 2014 Published online 1 October 2014 Published in print 1 October 2014